Trial Profile
A Phase 2, Open-Label, Single-Arm Rollover Study to Evaluate Long-Term Safety in Subjects Who Participated in Other Celgene Sponsored CC-486 (Oral Azacitidine) Clinical Trials in Hematological Disorders
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Dec 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 12 Jan 2023 Planned End Date changed from 31 Mar 2022 to 3 Jan 2026.
- 12 Jan 2023 Planned primary completion date changed from 31 Mar 2022 to 3 Jan 2026.
- 02 Dec 2021 Planned primary completion date changed from 28 Feb 2021 to 31 Mar 2022.